Mucolytics for children with chronic suppurative lung disease

Esther McElrea; Anne B. Chang; Stephanie Yerkovich; Hannah E. O'Farrell; Julie M. Marchant

doi:10.1002/14651858.CD015313

Mucolytics for children with chronic suppurative lung disease

Esther McElrea, Anne B. Chang, Stephanie Yerkovich, Hannah E. O'Farrell, Julie M. Marchant

Research output: Contribution to journal › Article › peer-review

Abstract

Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of mucolytics for reducing exacerbations and improving quality of life in children with CSLD (including PBB and bronchiectasis), and to assess the risk of harm due to adverse events.

Original language	English
Article number	CD015313
Pages (from-to)	1-13
Number of pages	13
Journal	Cochrane Database of Systematic Reviews
Volume	2022
Issue number	7
DOIs	https://doi.org/10.1002/14651858.CD015313
Publication status	Published - 25 Jul 2022

Bibliographical note

Funding Information:
EM: none known AC: received (via her institution) a grant from the European Respiratory Society SY: none known HO: none known JM: received a grant fellowship in bronchiectasis research from the Australian Lung Foundation.

Funding Information:
This project was supported by the National Institute for Health and Care Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health and Social Care.

Publisher Copyright:
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/14651858.CD015313

Cite this

@article{2e78e21ca4e34e0395f24fabe40b7e28,

title = "Mucolytics for children with chronic suppurative lung disease",

abstract = "Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of mucolytics for reducing exacerbations and improving quality of life in children with CSLD (including PBB and bronchiectasis), and to assess the risk of harm due to adverse events.",

author = "Esther McElrea and Chang, {Anne B.} and Stephanie Yerkovich and O'Farrell, {Hannah E.} and Marchant, {Julie M.}",

note = "Funding Information: EM: none known AC: received (via her institution) a grant from the European Respiratory Society SY: none known HO: none known JM: received a grant fellowship in bronchiectasis research from the Australian Lung Foundation. Funding Information: This project was supported by the National Institute for Health and Care Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health and Social Care. Publisher Copyright: Copyright {\textcopyright} 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.",

year = "2022",

month = jul,

day = "25",

doi = "10.1002/14651858.CD015313",

language = "English",

volume = "2022",

pages = "1--13",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley & Sons",

number = "7",

}

TY - JOUR

T1 - Mucolytics for children with chronic suppurative lung disease

AU - McElrea, Esther

AU - Chang, Anne B.

AU - Yerkovich, Stephanie

AU - O'Farrell, Hannah E.

AU - Marchant, Julie M.

N1 - Funding Information: EM: none known AC: received (via her institution) a grant from the European Respiratory Society SY: none known HO: none known JM: received a grant fellowship in bronchiectasis research from the Australian Lung Foundation. Funding Information: This project was supported by the National Institute for Health and Care Research (NIHR), via Cochrane Infrastructure funding to the Cochrane Airways Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS, or the Department of Health and Social Care. Publisher Copyright: Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

PY - 2022/7/25

Y1 - 2022/7/25

N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of mucolytics for reducing exacerbations and improving quality of life in children with CSLD (including PBB and bronchiectasis), and to assess the risk of harm due to adverse events.

AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effects of mucolytics for reducing exacerbations and improving quality of life in children with CSLD (including PBB and bronchiectasis), and to assess the risk of harm due to adverse events.

UR - http://www.scopus.com/inward/record.url?scp=85134917711&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD015313

DO - 10.1002/14651858.CD015313

M3 - Article

AN - SCOPUS:85134917711

SN - 1465-1858

VL - 2022

SP - 1

EP - 13

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 7

M1 - CD015313

ER -

Mucolytics for children with chronic suppurative lung disease

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this